Levothyroxine in Nephrotic syndrome

Comparing the effect of adding levothyroxine to steroids versus steroids alone on reducing the duration of relapse requiring hospitalization in children with nephrotic syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201112049368N2

Enrollment

Registered

2024-05-30

Start date

2022-11-23

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic Syndrome. Nephrotic syndrome

Interventions

Intervention 1: Intervention group: The intervention group will be treated from the time of hospitalization due to recurrence with an oral levothyroxine tablet manufactured by Iran Hormone Company at

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: idiopathic nephrotic syndrome Relapse requiring hospitalization serum TSH grater than 5.5 mIU/L

Exclusion criteria

Exclusion criteria: congenital nephrotic syndrome Secondary nephrotic syndrome GFR less than 60 ml/min/1.73 m2 confirmed hypothyroidism before the diagnosis of nephrotic syndrome

Design outcomes

Primary

Measure	Time frame
Relapse duration. Timepoint: during the whole period of study. Method of measurement: Urinary dipstick test.	—

Secondary

Measure	Time frame
Cumulative dose of prednisolon. Timepoint: At the incidence of remission. Method of measurement: recorded medical instructions and nursing report.;Cumulative dose of albumin. Timepoint: During relapses. Method of measurement: recorded medical instructions and nursing report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Taheri

Artesh University of Medical Sciences

amin.taheri2731@gmail.com+98 51 5422 2821

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026